Loading...
•
Jun 30, 2023
Ultragenyx Q2 2023 Earnings Report
Ultragenyx reported Q2 2023 financial results with total revenue of $108.3 million, a 21% increase compared to Q2 2022.
Key Takeaways
Ultragenyx reported a total revenue of $108.3 million for the second quarter of 2023, representing a 21% increase compared to the second quarter of 2022. Crysvita revenue in North America grew by 19% to $61.3 million. The company reaffirmed its 2023 total revenue guidance between $425 million and $450 million.
Total revenue for Q2 2023 was $108.3 million, a 21% increase year-over-year.
Crysvita revenue for Q2 2023 was $83.0 million, a 20% increase year-over-year.
Dojolvi revenue for Q2 2023 was $16.5 million.
The company reaffirmed its 2023 revenue guidance for total revenue, Crysvita, and Dojolvi.
Ultragenyx
Ultragenyx
Ultragenyx Revenue by Segment
Revenue by Segment
Crysvita Revenue
CapyFin.comDojolvi Revenue
CapyFin.comEvkeeza Revenue
CapyFin.comMepsevii Revenue
CapyFin.com Forward Guidance
The company expects total revenue to be in the range of $425 million to $450 million, Crysvita revenue in the range of $325 million to $340 million, and Dojolvi revenue in the range of $65 million to $75 million for the full year 2023. Net cash used in operations is expected to be around $400 million.
Positive Outlook
- Total revenue in the range of $425 million to $450 million
- Crysvita revenue in the range of $325 million to $340 million.
- Dojolvi revenue in the range of $65 million to $75 million
- Net Cash Used in Operations to be around $400 million
- Two Phase 3 studies enrolling, additional Phase 2 data expected in mid-October
Revenue & Expenses
Visualization of income flow from segment revenue to net income